Using the AACR Health Disparities Report to Drive Change in Cancer Care

Commentary
Video

The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.

The American Association for Cancer Research (AACR) Health Disparities Report is a powerful tool that can help educate those in the oncology community on health equity issues among patients with cancer, according to Robert A. Winn, MD.

Winn described his experiences with organizing the AACR Health Disparities Reports since the publication of the first in 2020. He stated that he was “happy” to be involved in this effort to help spread awareness of cancer disparities.

Winn, director and Lipman Chair in Oncology at Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center, senior associate for Cancer Innovation, and professor of Pulmonary Disease and Critical Cancer Medicine at VCU School of Medicine, also touched on how working with other professional bodies such as the American Cancer of Clinical Oncology (ASCO) may achieve the goal of educating others on heath disparity issues in oncology.

Transcript:

The education part of this is exciting for us. I hope that the AACR Health Disparities Report is just 1 tool to not only get my colleagues but to get people within the community and get those people who are in charge of our resources a little bit more up-to-speed and aware. This report has, on its own, been substantiated. I was part of the first one in 2020, and part of the second one in 2022. I’m happy to be part of [the 2023] one as well and leading the charge of the 2024 report. That’s one element that we hope will be able to help educate people and bring awareness. The other one is just [the] good old-fashioned [strategy of] having our professional bodies, whether they’re AACR, AACI [Association of American Cancer Institutes], American Cancer Society, or ASCO [American Society of Clinical Oncology] all working on one accord, and that is to bring to the attention that cancer is not like it used to be in the 1950s. It is not necessarily a death sentence if you can get to the right place and get the right care at the right time.

Reference

Experts forecast 2024, part 2: achieving cancer health equity. News release. AACR. January 12, 2024. Accessed February 16, 2024. https://shorturl.at/cMQR8

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Related Content